The short version
- Why people research itInsomnia disorder and for depressive symptoms in major depressive disorder with insomnia symptoms, by selectively blocking the orexin-2 receptor that carries wake-promoting drive.
- What the evidence isThe sleep effect is the best-established thing about this molecule, and it was measured with polysomnography rather than questionnaires.
- What to watchSudden muscle weakness with laughter or strong emotion.
How Seltorexant works
Selective antagonist at the orexin-2 receptor (OX2R). Orexin-A and orexin-B, the two wake-promoting peptides made in the lateral hypothalamus, signal through OX1R and OX2R; orexin-A engages both, orexin-B is OX2R-preferring, and OX2R is the receptor that carries arousal drive into the histaminergic and monoaminergic wake-promoting nuclei. Blocking it withdraws the wake signal instead of adding sedation, which is mechanically different from every GABA-A hypnotic — there is no chloride channel, no benzodiazepine site. Reported selectivity is an approximate 2-log ratio over the human orexin-1 receptor, and that single difference is the whole argument for the molecule: the three approved orexin drugs block both receptors. Target specificity was established genetically rather than by selectivity ratio alone — the compound promoted sleep in wild-type mice and had no effect in OX2R knockout mice. It did not raise dopamine in rat nucleus accumbens and did not produce place preference, in contrast to zolpidem run alongside it.
This molecule takes a foot off the accelerator instead of pressing a brake, and that is not a metaphor — it is the difference between two receptor families. Two peptides made in the lateral hypothalamus, orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2), hold the brain awake by signaling through two G-protein-coupled receptors, OX1R and OX2R.
The selectivity is the entire design claim, and it is a number rather than an adjective. Bonaventure 2015 characterized the compound under its development code JNJ-42847922 — chemically [5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone — and reported an approximate 2-log selectivity ratio versus the human orexin-1 receptor. The three orexin drugs that reached approval — suvorexant, lemborexant and daridorexant — block both receptors.
- Oral
On the goal map: HPA axis & cortisol regulation (Mood & stress resilience)
Research on Seltorexant14 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (Phase 3 primary endpoint met in MDD with insomnia symptoms — Johnson & Johnson; Phase 2 polysomnography in insomnia disorder, 364 randomized).
Human clinical evidence
The sleep effect is the best-established thing about this molecule, and it was measured with polysomnography rather than questionnaires. In insomnia disorder without psychiatric comorbidity. On night 1, 0.41-0.64), 0.57-0.88). Wake after sleep onset over the first 6 hours moved the same way. Which is the more interesting result, because tolerance is the standard objection to a hypnotic.
Across that same trial.
An earlier crossover put numbers on the same effect twice over. In insomnia disorder, both p < 0.001, with total sleep time up 27.7 and 37.9 minutes and latency to persistent sleep down 18.8 and 29.9 minutes. In antidepressant-treated patients with persistent insomnia, which is the first sign of the flat top that runs through this whole program.
The depression program is real, phase 3 met its primary endpoint, and the peer-reviewed record still lags the press release. Johnson & Johnson reported on 29 May 2024 that study MDD3001 — produced a statistically significant improvement in MADRS total score at day 43. That topline was presented at a congress and announced by the sponsor. A primary peer-reviewed publication of MDD3001 was not located as of 29 September 2026, so the phase 3 result is cited here as a sponsor announcement, which is what it currently is.
The randomized evidence that IS peer-reviewed for mood is phase 2b and phase 1b, and it is honestly mixed. P = .003) at week 3 but -3.1 (-6.13 to -0.16, P = .083) at week 6, i.e. the primary timepoint did not clear a conventional threshold. The signal concentrated where the mechanism predicts: in patients with baseline Insomnia Severity Index >= 15 the difference was -4.9 (-8.98 to -0.80), versus -0.7 (-5.16 to 3.76) in those below 15. P = 0.0456, with the benefit again greater at higher baseline insomnia severity (nominal p = 0.0059) and still present when sleep items were removed from the scale (nominal p = 0.0289).
Against an active comparator it won on tolerability, not on efficacy. Both added to ongoing SSRI/SNRI) reported treatment-emergent adverse events in 65.4% on seltorexant versus 80.8% on quetiapine-XR and all-cause discontinuation of 41.2% versus 47.1% (p = .5355). The sponsor's 22 September 2025 release on the 26-week phase 3 MDD3005 reported response at 26 weeks of 57.4% versus 53.4% for quetiapine-XR — numerically higher and not statistically significant — with MADRS total score changes from baseline of -23.0 and -22.7, somnolence in 6% versus 24%, and mean weight change of +0.5 kg versus +2.1 kg.
Correlative data
The entire human case rests on trials, so there is little genuinely correlative material — and that is worth stating rather than padding. The one association that recurs across three independent studies is internal to those trials: the antidepressant effect is moderated by how badly the patient was sleeping at baseline. Higher baseline insomnia severity predicted larger mood improvement in the phase 2b adjunctive study, in the phase 1b monotherapy study, and it is the population the phase 3 program was deliberately enriched for.
That moderation is the page's central unresolved question, and it is not resolvable from the data as published. A drug that fixes sleep in depressed people with broken sleep will improve depression scales partly because those scales contain sleep items and partly because sleep loss worsens mood. The phase 1b study addressed the first half — the benefit survived removing sleep items from HDRS — at nominal significance in an enriched sample of 86. Nobody has addressed the second half, which would need a non-orexin hypnotic matched for sleep improvement as the comparator.
The biomarker observation that points at a route other than sedation. One arm of one study, and it is the kind of finding that either replicates into a mechanism or evaporates — but it is the only published human signal suggesting the mood effect runs through something other than more hours asleep.
How the mechanism reads
The selectivity argument, stated precisely. Orexin-A and orexin-B drive wakefulness through OX1R and OX2R. OX2R is the receptor feeding the histaminergic and monoaminergic arousal nuclei; OX1R is more associated with reward, appetite and stress circuitry. Blocking OX2R alone is meant to buy sleep without the OX1R consequences — and, on one reading, without the REM distortion of a dual blocker. Reported selectivity is roughly 2 logs over human OX1R.
MechanisticThe preclinical package is unusually clean on target specificity. In rats, which is the rodent version of no rebound. The compound promoted sleep in wild-type mice and had no effect in OX2R knockout mice — target engagement proven by genetics rather than by a binding ratio.
Experimental, animal or cellThe abuse-liability argument is mechanistic and was tested against the obvious comparator. Seltorexant did not increase dopamine release in rat nucleus accumbens and did not produce conditioned place preference, while zolpidem in the same program did. Withdrawing a wake signal is not the same lever as potentiating GABA-A, and this is the experiment that shows the difference behaviorally.
Experimental, animal or cellThe literature contradicts itself on whether OX2R selectivity spares REM sleep, and the contradiction is the most useful thing on this page. One rat study found an OX2R antagonist increased non-REM duration with REM unaffected, and that adding an OX1R antagonist on top reduced REM latency and increased REM at the expense of non-REM — framed explicitly as dysregulation, and the strongest published case for going OX2R-selective. A separate program reached the opposite conclusion with a different OX2R-selective molecule, reporting that OX2R antagonism alone increased both non-REM and REM across rats, dogs and humans, similar to dual blockade. Both are real results with real molecules. What follows is that 'selective, therefore preserves sleep architecture' is a hypothesis this compound's own class has not settled.
Experimental, animal or cellWhatever the class argument.
Mechanistic
Sources
- Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. Journal of Pharmacology and Experimental Therapeutics 2015;354(3):471-82 · PMID 26177655
- De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Benes H, Keicher C, Jahn H, Seiden DJ, Luthringer R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of Psychopharmacology 2018;32(6):668-677 · PMID 29848147
- van der Ark PD, Golor G, van Nueten L, Nandy P, de Boer P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. Journal of Psychopharmacology 2018;32(12):1330-1340 · PMID 30182786
- Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of Psychopharmacology 2019;33(2):202-209 · PMID 30644312
- Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, Drevets WC. International Journal of Neuropsychopharmacology 2021;24(12):965-976 · PMID 34324636
- Mesens S, Kezic I, Van Der Ark P, Etropolski M, Pandina G, Benes H, Savitz A, Drevets WC. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Molecular Psychiatry 2024; published online 11 December 2024 (doi 10.1038/s41380-024-02846-5) · PMID 39663378
- Mesens S, Krystal AD, Melkote R, Xu H, Pandina G, Saoud JB, Luthringer R, Savitz A, Drevets WC. Efficacy and Safety of Seltorexant in Insomnia Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025; published online 13 August 2025 (doi 10.1001/jamapsychiatry.2025.1999) · PMID 40802194
- Pinter C, Thase ME, McIntyre RS, Cooper K, Xu H, Pandina G, Savitz A, Drevets WC. International Journal of Neuropsychopharmacology 2026; published online 9 March 2026 (doi 10.1093/ijnp/pyag009) · PMID 41795948
- Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Frontiers in Neuroscience 2014;8:28 · PMID 24592208
- Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Scientific Reports 2016;6:27147 · PMID 27256922
Seltorexant safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Narcolepsy or cataplexy: orexin signaling is already lost in those conditions.
- Depression with suicidal thoughts: sleep and mood drugs need monitoring, not self-management.
- Strong CYP3A4 inhibitors: they raise seltorexant levels.
- Alcohol or sedative use: wake-drive withdrawal stacks with them.
- Pregnancy: blocking orexin-2 in a developing sleep-wake system is untested.
What’s expected
- Falling asleep more easily, because OX2R blockade removes wake signal rather than adding sedation.
- Next-morning drowsiness.
- Vivid dreams or sleep paralysis, a class effect.
- Headache.
Watch for
- Sudden muscle weakness with laughter or strong emotion.
- Waking paralyzed with hallucinations.
- Drowsiness that makes driving unsafe.
- Worsening mood while using Seltorexant.
Labs that tell you it’s working
- Cortisol
- TSH (Thyroid-Stimulating Hormone)
- Vitamin D (25-Hydroxy)
- Comprehensive Metabolic Panel (CMP)
Seltorexant is a selective orexin-2 receptor antagonist, unlike dual blockers; narcolepsy-like effects and next-day sedation follow from orexin withdrawal. PMID 34324636 PMID 39663378
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Seltorexant FAQ4 common questions
- Is Seltorexant approved for human use?
- No. Seltorexant is a research compound.
- What is Seltorexant researched for?
- Insomnia disorder and for depressive symptoms in major depressive disorder with insomnia symptoms, by selectively blocking the orexin-2 receptor that carries wake-promoting drive.
- Which labs show whether it's doing anything?
- Cortisol; TSH; Vitamin D; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Seltorexant: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



